
    
      Approximately ninety-nine (99) subjects meeting the inclusion/exclusion criteria will be
      randomized in a 2:1 ratio to either the active or sham group. Randomization will be
      stratified by study site, with a maximum of 21 subjects randomized in an individual site.
      Subjects will be followed up with at 10 days and at 3 and 6 months post-treatment. Subjects
      will be assessed for adverse events at all study contacts and visits from the time the
      informed consent is signed.
    
  